If you have been injecting basal insulin every day and are ready to switch to once-weekly Awiqli (insulin icodec), this guide walks you through the specific protocols for making the transition safely. The switch is well-studied and straightforward, but the details matter — especially during the first 3–4 weeks as Awiqli builds to steady-state levels in your body.
Quick Answer
Stop your daily insulin. Calculate your first Awiqli dose based on your current daily dose × 7, with adjustments based on which insulin you are switching from. Give the first Awiqli injection the day after your last daily injection. Expect steady-state insulin levels to be reached in 3–4 weeks. Monitor fasting blood glucose daily for the first month. Do not panic-adjust based on early fluctuations — let the drug reach steady state before making dose changes.
FDA Approval Context
Awiqli (insulin icodec) received FDA approval in March 2026 for adults with type 2 diabetes requiring basal insulin therapy. It is manufactured by Novo Nordisk and represents the first once-weekly insulin approved in the United States. The approval was based on the ONWARDS trial program, which demonstrated non-inferiority to Lantus (insulin glargine) across multiple patient populations.
Important: Awiqli is approved for type 2 diabetes only. It is not currently approved for type 1 diabetes or pediatric use.
Transition Protocols by Current Insulin
Switching from Lantus (Insulin Glargine U100)
Lantus has a half-life of 12–14 hours. After your last injection, levels decline over approximately 24 hours. The transition is straightforward:
- Take your last Lantus injection on your normal schedule
- Calculate your first Awiqli dose: Current daily Lantus dose × 7
- Example: 30 units/day Lantus → 210 units first Awiqli dose
- Example: 40 units/day Lantus → 280 units first Awiqli dose
- Inject Awiqli the day after your last Lantus injection
- Continue weekly Awiqli on the same day each week
The first dose may be slightly higher than your eventual maintenance dose because Awiqli takes 3–4 weeks to reach steady state. Your provider may adjust after the first 2–3 doses.
Switching from Tresiba (Insulin Degludec)
Tresiba has a longer half-life (~25 hours) and takes 3–4 days to fully clear. This creates potential for overlap with Awiqli during the first week.
- Take your last Tresiba injection as scheduled
- Calculate first Awiqli dose: Current daily Tresiba dose × 7, then reduce by 20%
- Example: 30 units/day Tresiba → 210 × 0.8 = 168 units first Awiqli dose
- Start Awiqli 3 days after your last Tresiba injection (not the next day, due to Tresiba's long half-life)
- Monitor closely for the first 2 weeks for hypoglycemia due to potential overlap
The 20% dose reduction accounts for the overlap period. Your provider will titrate up to the full equivalent dose over the first 2–3 weeks.
Switching from Levemir (Insulin Detemir)
Levemir has the shortest half-life (~6–8 hours) among common basal insulins. The transition is the simplest:
- Take your last Levemir injection as scheduled
- Calculate first Awiqli dose: Current total daily Levemir dose × 7
- If you inject twice daily, add both doses: e.g., 15 units AM + 15 units PM = 30 units/day → 210 units first Awiqli dose
- Start Awiqli the day after your last Levemir injection
Loading Period: The First 3–4 Weeks
Unlike daily insulins that reach steady state within 1–2 days, Awiqli takes 3–4 weekly doses to reach steady-state plasma levels. During this loading period:
- Insulin levels are building but have not plateaued
- Fasting glucose may run slightly higher than expected, especially on days 4–7 of each week
- The first 1–2 doses provide less 24/7 coverage than what you will experience at steady state
- Your provider may prescribe a slightly higher first dose (some protocols use daily dose × 7 × 1.5 for the very first injection, then drop to daily dose × 7 for subsequent doses)
The most important thing during this period is patience. Do not overreact to slightly elevated fasting glucose in Week 1–2 by adding extra insulin or reverting to daily insulin. The drug is working — it just has not reached full effect yet.
Blood Sugar Monitoring During the Switch
- Weeks 1–4: Check fasting blood glucose every morning. This is non-negotiable during the transition.
- CGM recommended: If you have access to a continuous glucose monitor, use it during the transition. CGM data provides far more useful information than fingerstick alone — you can see overnight trends, post-meal patterns, and early signs of hypoglycemia.
- Target fasting glucose: 80–130 mg/dL (per ADA guidelines). If fasting glucose consistently runs above 180 mg/dL after 3 weeks, contact your provider for dose adjustment.
- Watch for hypoglycemia: Report any glucose readings below 70 mg/dL immediately, especially in the first 2 weeks if switching from Tresiba (overlap risk).
What Happens to Your Blood Sugar
Realistic expectations during the transition:
- Days 1–3 after first dose: You may see slightly higher-than-usual fasting glucose. This is normal — Awiqli is still building in your system.
- Days 4–7: Some improvement, but not yet at steady state. Fasting glucose may fluctuate more than you are used to.
- Weeks 2–3: Glucose patterns begin to stabilize. You should see more consistent fasting numbers.
- Week 4+: Steady state reached. Your glucose profile should resemble (or improve upon) what you achieved with daily insulin.
Do not add supplemental daily insulin during the transition unless specifically instructed by your provider. Adding insulin while Awiqli is building up creates stacking risk and potential hypoglycemia.
Insurance Coverage in 2026
As a newly approved medication, Awiqli faces the typical coverage landscape for new drugs:
- Prior authorization required: Nearly all plans require PA documentation including current insulin regimen, A1c, and medical necessity
- Medicare Part D: Expected to cover Awiqli with PA. Co-pay will depend on plan formulary tier (likely Tier 3–4)
- Commercial insurance: Coverage varies. Some plans will cover it readily; others may require step therapy (documented trial of daily insulin first — which you presumably have)
- Novo Nordisk NovoCare: Patient assistance programs offering copay cards ($25–$50/month for eligible commercially insured patients) and free medication for qualifying uninsured patients
Start the PA process before your intended switch date — allow 1–2 weeks for processing.
Common Questions
What if I forget my weekly Awiqli dose?
If you realize within 3 days (72 hours) of your scheduled dose, take it as soon as possible. Then resume your regular weekly schedule. If more than 3 days have passed, skip the missed dose and take the next one on your regular schedule. Do not double up.
Because of Awiqli's 8-day half-life, missing a single dose by 1–2 days does not cause an immediate insulin gap the way missing daily insulin would. You have more buffer — but do not make it a habit.
Can I use Awiqli with mealtime insulin?
Yes. Awiqli replaces your basal insulin only. If you take rapid-acting insulin with meals (insulin aspart, lispro, glulisine), continue your mealtime insulin as prescribed. Awiqli handles the background glucose control; mealtime insulin handles post-meal spikes.
What about sick days?
During illness (infections, fever, vomiting), insulin requirements change. Since Awiqli cannot be adjusted daily, your provider may recommend supplemental rapid-acting insulin during acute illness, or temporary return to daily basal insulin. Have a sick-day plan in place before you need one.
Can I use Awiqli with GLP-1 medications?
Yes. Awiqli can be used alongside GLP-1 receptor agonists (Ozempic, Mounjaro, Foundayo) if your diabetes management requires both basal insulin and GLP-1 therapy. This combination is becoming increasingly common in type 2 diabetes.
How long until I know if Awiqli is working for me?
Give it a full 6–8 weeks before evaluating. The first 3–4 weeks are the loading period, and the next 2–4 weeks reflect true steady-state performance. Check A1c at 3 months for a definitive assessment.
Bottom Line
Switching from daily insulin to weekly Awiqli is a straightforward process with well-established protocols. The key is proper dose conversion, patience during the 3–4 week loading period, and consistent blood sugar monitoring. For type 2 diabetes patients tired of daily injections, Awiqli is a meaningful quality-of-life improvement.
Talk to your endocrinologist or diabetes care team about whether Awiqli is appropriate. Bring your current insulin dose, recent A1c, and insurance card. The switch to weekly insulin starts with one conversation.